Amgen Inc. Share Price

Amgen Inc. Share Price

NASDAQ: AMGN | Mega Cap
$461.82
+$10.04 (2.22%) Last updated on 30 Oct, 2026 | 01:31 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Amgen Inc. Stock Performance

Open
$465.00
Prev. Close
$451.78
Circuit Range
N/A
Day Range
$457.40 - $467.71
Year Range
$288.75 - $467.71
Volume
98,389
Average Traded
$462.18

Amgen Inc. Share Price Today

As of 30 October 2026, Amgen Inc.'s share price is $461.82. The stock opened at $465.00, compared to its previous close of $451.78. During today's trading session, Amgen Inc.'s share price traded between $457.40 and $467.71, with an average price of $462.55. Over the past 52 weeks, the stock has recorded a high of $467.71 and a low of $288.75. In terms of performance, Amgen Inc.'s share price has risen by 33.39% over the last six months and is up 54.74% on a year-on-year basis.

Amgen Inc. Share Price Chart

Line chart of the Amgen Inc. price trend over the selected period. The price rose overall, ranging from 457.40 to 469.76, ending at 460.63.
$457.40$467.71
L
Show Current Price
H

Amgen Inc. Stock Fundamentals & Key Indicators

Market Cap
$248.46B
PE Ratio (TTM)
27.94
Dividend Yield
2.16%
EPS (TTM)
$16.17
Revenue (TTM)
$36.75B
Return On Equity (TTM)
74.80%
Profit Margin
20.98%
Debt to Equity
4.90
Quarterly Earnings Growth YoY
-26.09%

Amgen Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$9.56$9.87$8.62$10.05
Net Profit$3.22$1.33$1.82$2.38
Net Profit Margin33.68%13.48%21.11%23.68%
Income ChangeN/A-58.70%36.84%30.77%

Amgen Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$26.32$28.19$33.42$36.75
Net Profit$6.55$6.72$4.09$7.71
Net Profit Margin24.89%23.84%12.24%20.98%
Income ChangeN/A2.60%-39.14%88.51%

About Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$421.95
$460.47
+9.10%
Sep 2026
$432.49
$422.08
-3.40%
Aug 2026
$389.64
$436.92
+13.42%
Jul 2026
$362.47
$385.21
+6.37%
Jun 2026
$333.00
$362.15
+7.54%
May 2026
$334.89
$336.77
-2.73%
Apr 2026
$354.90
$346.22
-1.61%
Mar 2026
$386.63
$351.87
-9.33%
Feb 2026
$340.82
$388.10
+13.48%
Jan 2026
$328.69
$341.99
+4.47%
Dec 2025
$343.14
$327.35
-5.23%
Nov 2025
$298.44
$345.43
+15.74%

AMGN Share Price FAQs